IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company, is set to announce topline results from its Phase 2 OVATION 2 Study on July 30, 2024, at 8:00 a.m. Eastern time. The study focuses on IMNN-001, the company's DNA-mediated immunotherapy for advanced ovarian cancer. IMNN-001 is an interleukin-12 (IL-12) immunotherapy based on IMUNON's TheraPlas™ technology.
Following the announcement, IMUNON will host an investment community conference call at 8:30 a.m. Eastern time to discuss the results and answer questions. Interested parties can participate by dialing 833-816-1132 (Toll-Free/North America) or 412-317-0711 (International/Toll). A live webcast and replay of the call will be available, with the replay accessible until August 13, 2024.
IMUNON, Inc. (NASDAQ: IMNN), una società in fase clinica, annuncerà i risultati preliminari dello Studio OVATION 2 di Fase 2 il 30 luglio 2024, alle 8:00 ora orientale. Lo studio si concentra su IMNN-001, l'immunoterapia mediata da DNA della società per il cancro ovarico avanzato. IMNN-001 è un'immunoterapia a base di interleuchina-12 (IL-12) che utilizza la tecnologia TheraPlas™ di IMUNON.
Successivamente all'annuncio, IMUNON ospiterà una conference call per la comunità degli investitori alle 8:30 ora orientale per discutere i risultati e rispondere alle domande. Le parti interessate possono partecipare componendo 833-816-1132 (numero verde/Nord America) o 412-317-0711 (internazionale/a pagamento). Sarà disponibile una diretta streaming e la registrazione della chiamata, con la registrazione accessibile fino al 13 agosto 2024.
IMUNON, Inc. (NASDAQ: IMNN), una empresa en etapa clínica, anunciará los resultados preliminares de su Estudio OVATION 2 de Fase 2 el 30 de julio de 2024, a las 8:00 a.m. hora del Este. El estudio se centra en IMNN-001, la inmunoterapia mediada por ADN de la compañía para el cáncer de ovario avanzado. IMNN-001 es una inmunoterapia de interleucina-12 (IL-12) basada en la tecnología TheraPlas™ de IMUNON.
Tras el anuncio, IMUNON llevará a cabo una conferencia telefónica para la comunidad de inversores a las 8:30 a.m. hora del Este para discutir los resultados y responder preguntas. Las partes interesadas pueden participar marcando el 833-816-1132 (gratis/Norteamérica) o el 412-317-0711 (Internacional/con cargo). Se ofrecerá una transmisión en vivo y la repetición de la llamada estará disponible, accesible hasta el 13 de agosto de 2024.
IMUNON, Inc. (NASDAQ: IMNN), 임상 단계 회사가 2상 OVATION 2 연구의 주요 결과를 2024년 7월 30일 오전 8시 동부 표준시(GMT-5)에 발표할 예정입니다. 이 연구는 IMNN-001, 이 회사의 난소암 치료를 위한 DNA 매개 면역요법에 중점을 두고 있습니다. IMNN-001은 IMUNON의 TheraPlas™ 기술을 기반으로 한 인터루킨-12 (IL-12) 면역요법입니다.
발표 이후 IMUNON은 투자 커뮤니티를 위한 전화 회의를 오전 8시 30분 동부 표준시에 개최하여 결과를 논의하고 질문에 답할 것입니다. 관심 있는 분들은 833-816-1132 (무료/북미) 또는 412-317-0711 (국제/유료)로 전화하여 참여할 수 있습니다. 실시간 웹캐스트와 통화 녹음이 제공되며, 통화 녹음은 2024년 8월 13일까지 액세스할 수 있습니다.
IMUNON, Inc. (NASDAQ: IMNN), une société en phase clinique, annoncera les résultats préliminaires de son étude de phase 2 OVATION 2 le 30 juillet 2024 à 8h00, heure de l'Est. L'étude se concentre sur IMNN-001, l'immunothérapie médiane par ADN de l'entreprise pour le cancer de l'ovaire avancé. IMNN-001 est une immunothérapie à base d'interleukine-12 (IL-12) basée sur la technologie TheraPlas™ d'IMUNON.
Après l'annonce, IMUNON animera une conférence téléphonique pour la communauté des investisseurs à 8h30, heure de l'Est, pour discuter des résultats et répondre aux questions. Les parties intéressées peuvent participer en composant le 833-816-1132 (sans frais/Nord-Amérique) ou le 412-317-0711 (international/tarif normal). Un webinaire en direct et un enregistrement de l'appel seront disponibles, l'enregistrement étant accessible jusqu'au 13 août 2024.
IMUNON, Inc. (NASDAQ: IMNN), ein Unternehmen in der klinischen Phase, wird am 30. Juli 2024 um 8:00 Uhr Eastern Time die ersten Ergebnisse seiner Phase 2 OVATION 2-Studie bekannt geben. Die Studie konzentriert sich auf IMNN-001, die DNA-vermittelte Immuntherapie des Unternehmens für fortgeschrittenen Eierstockkrebs. IMNN-001 ist eine Immuntherapie mit Interleukin-12 (IL-12), die auf der TheraPlas™-Technologie von IMUNON basiert.
Nach der Bekanntgabe wird IMUNON eine Telefonkonferenz für die Investoren-Community um 8:30 Uhr Eastern Time abhalten, um die Ergebnisse zu diskutieren und Fragen zu beantworten. Interessierte können teilnehmen, indem sie 833-816-1132 (gebührenfrei/Nordamerika) oder 412-317-0711 (international/gebührenpflichtig) wählen. Eine Live-Übertragung und eine Wiederholung des Anrufs werden verfügbar sein, wobei die Wiederholung bis zum 13. August 2024 zugänglich ist.
- Phase 2 clinical trial results for IMNN-001 in advanced ovarian cancer to be announced
- Company reaching late-stage development with its DNA-mediated immunotherapy
- Investor conference call scheduled to discuss results, indicating transparency and engagement with shareholders
- None.
Results to be announced at 8:00 a.m. Eastern time, conference call to begin at 8:30 a.m. Eastern time
LAWRENCEVILLE, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, will issue a news release announcing topline results from the Phase 2 OVATION 2 Study with IMNN-001 in patients with advanced ovarian cancer tomorrow, July 30, at approximately 8:00 a.m. Eastern time, and will host an investment community conference call to discuss the results and answer questions at 8:30 a.m. Eastern time. IMNN-001 is the Company’s interleukin-12 (IL-12) immunotherapy based on its TheraPlas™ technology.
To participate in the conference call, please dial 833-816-1132 (Toll-Free/North America) or 412-317-0711 (International/Toll) and ask for the IMUNON call. A live webcast of the call will be available here.
Participants are encouraged to preregister for the call here.
The call will be archived for replay through August 13, 2024. The replay can be accessed at 877-344-7529 (U.S. Toll-Free), 855-669-9658 (Canada Toll-Free) or 412-317-0088 (International Toll), using the replay access code 7783601. A webcast of the call will be available here for 90 days.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the delivery of DNA-coded viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101). IMUNON will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Contacts:
| IMUNON | LHA Investor Relations |
| David Gaiero | Kim Sutton Golodetz |
| 978-376-6352 | 212-838-3777 |
| dgaiero@imunon.com | kgolodetz@lhai.com |
# # #
FAQ
When will IMUNON (IMNN) announce the Phase 2 OVATION 2 Study results for IMNN-001?
What is IMNN-001 and what condition is it targeting in the OVATION 2 Study?
How can investors participate in IMUNON's (IMNN) conference call on July 30, 2024?
Until when will the replay of IMUNON's (IMNN) July 30, 2024 conference call be available?
